Upstream / Downstream

pathwayImage

Explore pathways related to this product.

Our U.S. Offices Will Be Closing Early

Our U.S. offices will be closing early on November 26th at 6:00 PM EST.

To Purchase # 8919SC

8919SC 10 µg (With Carrier)
8919SF 10 µg (Carrier Free)
8919LC 50 µg (With Carrier)
8919LF 50 µg (Carrier Free)

To get local purchase information on this product, click here

Questions?

Find answers on our FAQs page.

ANSWERS  

Visit PhosphoSitePlus®

PTM information and tools available.

LEARN MORE

Source / Purification

Recombinant human IL-4 (hIL-4) His25-Ser153 (Accession #AF395008) was expressed in human 293 cells at Cell Signaling Technology.

Product Description

Purity:

>98% as determined by SDS-PAGE of 6 μg reduced (+) and non-reduced (-) recombinant hIL-4. All lots are greater than 98% pure.


Molecular Formula:

Recombinant hIL-4 does not have a Met on the amino terminus and the nonglycosylated protein has a calculated MW of 14,963. DTT-reduced and non-reduced protein migrate as larger 20 kDa polypeptides due to glycosylation, with non-reduced having slightly greater mobility due to an intramolecular cystine. The expected amino-terminal HKCDI of recombinant hIL-4 was verified by amino acid sequencing.


Bioactivity:

The bioactivity of recombinant hIL-4 was determined in a TF-1 cell proliferation assay. The ED50 of each lot is between 80-250 pg/ml.


Endotoxin:

Less than 0.01 ng endotoxin/1 μg hIL-4.


Product Usage Information

Formulation:

With carrier: Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.2 containing 20 μg BSA per 1 μg hIL-4. Carrier free: Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.2.


Storage: Stable in lyophilized state at 4°C for 1 year after receipt. Sterile stock solutions reconstituted with carrier protein are stable at 4°C for 2 months and at -20°C for 6 months. Avoid repeated freeze-thaw cycles.Maintain sterility. Storage at -20°C should be in a manual defrost freezer.

IL-4 is produced by T cells, NK T cells, γδ cells, and mast cells (1). Target cells include B cells, T cells, and macrophages (1). IL-4 induces differentiation of naive T cells into the TH2 phenotype. IL-4 also promotes B cell proliferation, antibody isotype switching and expression of other TH2 cytokines including IL-5 and IL-9. IL-4 induced TH2 polarization is important in developing humoral immunity against extracellular pathogens (1) and is involved in the development of allergy and asthma (2). IL-4 binds to two distinct receptors, the type I receptor and type II receptor. Type I receptor is a heterodimer consisting of IL-4Rα chain and the common gamma chain, γc (3,4). Type II receptor, which is shared with IL-13, is a heterodimer of IL-4Rα and IL-13Rα1. Signaling initiated via type I receptor results in the activation of Jak1/Stat6, Jak3 and the PI3K/Akt pathways (3). The type II receptor activates the Jak1/Stat6 and the Tyk2/Stat3 pathways (3).


1.  Corthay, A. (2006) Scand J Immunol 64, 93-6.

2.  Nakajima, H. and Takatsu, K. (2007) Int Arch Allergy Immunol 142, 265-73.

3.  Wills-Karp, M. and Finkelman, F.D. (2008) Sci Signal 1, pe55.

4.  Mueller, T.D. et al. (2002) Biochim Biophys Acta 1592, 237-50.


Entrez-Gene Id 3565
Swiss-Prot Acc. P05112


For Research Use Only. Not For Use In Diagnostic Procedures.
Cell Signaling Technology® is a trademark of Cell Signaling Technology, Inc.